
Last updated: 2026-09-22 13:04:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Filana Therapeutics, Inc. (FLNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.96, with a market capitalization of $35.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.67 to $2.27. This page covers its latest market performance, valuation, price trends and company information.
$35.07M | |
$0.75 | |
$2.27 | |
$0.67 | |
$0.74 | |
14.01M | |
314.40K | |
-- | |
$2.27 | |
$0.67 | |
-- | |
-- |
Filana Therapeutics, Inc. (FLNA) is trading at $0.96 in pre-market trading as of 2026-09-22 13:03:00, up 29.28% ($0.22) from the previous close of $0.74
Pre-market trading shows how investors are pricing FLNA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Filana Therapeutics, Inc. (FLNA) moved from $0.77 to $0.96, representing a gain of 23.87% ($0.18).
The stock traded between $0.67 and $1.10 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 322.86 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 18.0%
FLNA is currently trading at $0.96, placing it 18.0% of the way from its 52-week low of $0.67 to its 52-week high of $2.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Filana Therapeutics, Inc. (FLNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.